Digital Aria Co Ltd (KQ:115450) — Market Cap & Net Worth
Market Cap & Net Worth: Digital Aria Co Ltd (115450)
Digital Aria Co Ltd (KQ:115450) has a market capitalization of $122.47 Million (₩180.72 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18519 globally and #843 in its home market, demonstrating a 2.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Digital Aria Co Ltd's stock price ₩2050.00 by its total outstanding shares 88154766 (88.15 Million). Also see how large is Digital Aria Co Ltd's balance sheet for a full breakdown of the balance sheet.
Digital Aria Co Ltd Market Cap History: 2015 to 2026
Digital Aria Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $373.65 Million to $122.47 Million (-7.67% CAGR). Also see Digital Aria Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Digital Aria Co Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$234.31 Billion | 0.05% | #326 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$234.31 Billion | 0.05% | #326 of 1384 |
Weight: Digital Aria Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Digital Aria Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Digital Aria Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Digital Aria Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Digital Aria Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $464.28 Million | $17.71 Billion | -$5.20 Billion | 0.03x | N/A |
| 2017 | $981.54 Million | $17.15 Billion | -$4.82 Billion | 0.06x | N/A |
| 2018 | $786.34 Million | $43.58 Billion | $4.57 Billion | 0.02x | 0.17x |
| 2019 | $872.79 Million | $58.97 Billion | -$16.42 Billion | 0.01x | N/A |
| 2020 | $814.23 Million | $42.93 Billion | -$16.90 Billion | 0.02x | N/A |
| 2021 | $394.57 Million | $43.59 Billion | -$17.20 Billion | 0.01x | N/A |
| 2022 | $323.24 Million | $48.13 Billion | -$11.35 Billion | 0.01x | N/A |
| 2023 | $261.97 Million | $52.59 Billion | -$2.30 Billion | 0.00x | N/A |
| 2024 | $699.57 Million | $54.93 Billion | -$22.79 Billion | 0.01x | N/A |
| 2025 | $179.22 Million | $69.56 Billion | -$9.23 Billion | 0.00x | N/A |
Competitor Companies of 115450 by Market Capitalization
Companies near Digital Aria Co Ltd in the global market cap rankings as of September 18, 2026. Review Digital Aria Co Ltd (115450) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Digital Aria Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Digital Aria Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Digital Aria Co Ltd's market cap moved from $373.65 Million to $ 122.47 Million, with a yearly change of -7.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩122.47 Million | -31.67% |
| 2025 | ₩179.22 Million | -74.38% |
| 2024 | ₩699.57 Million | +167.05% |
| 2023 | ₩261.97 Million | -18.96% |
| 2022 | ₩323.24 Million | -18.08% |
| 2021 | ₩394.57 Million | -51.54% |
| 2020 | ₩814.23 Million | -6.71% |
| 2019 | ₩872.79 Million | +10.99% |
| 2018 | ₩786.34 Million | -19.89% |
| 2017 | ₩981.54 Million | +111.41% |
| 2016 | ₩464.28 Million | +24.25% |
| 2015 | ₩373.65 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Digital Aria Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $122.47 Million USD |
| MoneyControl | $122.47 Million USD |
| MarketWatch | $122.47 Million USD |
| marketcap.company | $122.47 Million USD |
| Reuters | $122.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more